Bioavailability: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
| Line 11: | Line 11: | ||
| url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.24 }}</ref> | | url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.24 }}</ref> | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}}[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 16:00, 18 July 2024
In pharmacology, Bioavailability is the degree to which a drug, nutrient or other biologically active substance becomes available to the target tissue after administration. [1] For bioavailability to be verified, there must be a chemical, biological, immunologic, or other test that verifies the concentration of the drug, or its active derivative, in the body fluids of the recipient.
Bioequivalence covers the case where the initial distribution of different drug preparations may vary, but the duration and form of the active principle is delivered identically. [2]
References
- ↑ Bioavailability
- ↑ , Subcapter D, Drugs for Human Use, Part 320: Bioavailability and Bioequivalence requirements, US Code of Federal Regulations, April 1, 2008, 21CFR320.24